Impact of GLP-1 Agonist Use on Non-Alcoholic Fatty Liver Disease Among Patients at a Large, Tertiary Care Center

Authors

Soorya N. Aggarwal, Lehigh Valley Health NetworkFollow
Matthew Sullivan DO, Lehigh Valley Health NetworkFollow
Michal Kloska MD, Lehigh Valley Health NetworkFollow
Angela Magdaleno DO, Lehigh Valley Health NetworkFollow
Gretchen A. Perilli MD, Lehigh Valley Health NetworkFollow
She-Yan Wong MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

10-2019

Volume

114

Issue

Supp

Published In/Presented At

Aggarwal, Soorya DO1; Sullivan, Matthew J. DO1; Kloska, Michal MD1; Magdaleno, Angela DO1; Perilli, Gretchen MD1; Wong, She-Yan MD2. 1078 Impact of GLP-1 Agonist Use on Non-Alcoholic Fatty Liver Disease Among Patients at a Large, Tertiary Care Center. The American Journal of Gastroenterology 114():p S610, October 2019. | DOI: 10.14309/01.ajg.0000593844.88418.01

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Fellows and Residents

Document Type

Article